Fulcrum Therapeutics to Present at the Annual Society for Neuroscience Meeting

November 10, 2017

Cambridge, Mass., November 10, 2017 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, will present at the Society for Neuroscience Annual Meeting held from November 11-15 in Washington, D.C.

The following three posters will be presented on November 14, 2017 from 1:00 to 5:00 p.m. ET at the Walter E. Washington Convention Center, in Halls A-C.

Hao Wu, Ph.D., Senior Scientist, will present a poster titled “Fragile X: Disease Predictors and Treatments” between 1 and 2 p.m.

Mark Roth, Senior Scientist, Translational Medicine, will present a poster titled “Development of sensitive and quantitative assays to detect FMRP in human iNeurons and tissues” between 3 and 4 p.m.

John Graef, Ph.D., Senior Manager, Cell Physiology, will present a poster titled “Functional assessment of spontaneous and evoked activity in iPSC-derived Fragile X neurons” between 4 and 5 p.m.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum, headquartered in Cambridge, Mass., was launched by Third Rock Ventures in 2016 and named a “Fierce 15” company later that year. For more information, please visit www.fulcrumtx.com.


Sarah Sutton
Ten Bridge Communications
[email protected]